Therefore, monotherapies using a BRAF inhibitor (BRAFi) or combination therapies of BRAF and MEK inhibitors (MAPKi) are now considered a mainstay of melanoma treatment (Long et al., 2015). Here, MAP2K7 is linked to melanoma.